Poly Medicure Limited has submitted to the Exchange, the Audited financial results(Standalone & Consolidated) for the period ended March 31, 2026.

Revenue growth above 20%Net loss reportedEBITDA margin compressionExceptional itemResults View source PDF Explain this filing

POLYMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.0%Reaction day

₹1600.00

prior close

₹1597.00

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.2%-6.2% vs market

Medical Equipment & Supplies peers, median of 11sector+0.1%-5.1% vs sector

On the reaction day the stock moved 6.2 pts less than Nifty Smallcap 250 and 5.1 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.5

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.0+1.2-6.2+0.1-5.1

Next day

-10.2+1.4-11.6-0.3-9.8

-17.2+2.0-19.1+0.8-17.9

-15.6+1.3-16.9-0.4-15.2

-17.2+0.5-17.7-3.7-13.5

-17.4+1.0-18.4-4.3-13.1

-11.6+1.7-13.2-6.4-5.1

15d

-5.4+3.5-8.9-5.8+0.5

+3.1+5.5-2.4-2.4+5.6

+4.7+6.3-1.6-1.7+6.3

+8.3+9.4-1.0+1.5+6.8

UpDownMarket · Nifty Smallcap 250Sector · Medical Equipment & Supplies peers, median of 11Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Poly Medicure reported FY2026 consolidated revenue of ₹5,345 crore, up 21% from ₹4,408 crore in FY2025, driven by new acquisitions including Pendracare Group (Netherlands) and Medlstream SA/Citieffe Group (Switzerland). Standalone revenue grew 21% to ₹4,430 crore. Net profit after tax on consolidated basis increased marginally to ₹3,386 crore from ₹3,313 crore, while standalone PAT declined to ₹3,360 crore from ₹3,385 crore. EPS (consolidated) dropped to ₹31.79 from ₹34.13, indicating margin compression despite revenue growth. The company recorded an exceptional item of ₹68.04 crore due to impact of new Labour Codes. Board recommended dividend of ₹3.5 per share (70%). QIP funds of ₹1,000 crore raised previously were deployed for acquisitions and capital expenditure.

Likely market impact

Revenue growth exceeds 20% but bottom-line declined or stagnated, suggesting margin pressure from acquisitions and Labour Code impact. The aggressive acquisition strategy is expanding scale but may weigh on near-term profitability and EPS.